PAI Partners enters into exclusive negotiations with Ergon Capital Partners for the acquisition of ELITech Group, a leading manufacturer of specialty in-vitro diagnostics equipment and reagents.
On May 11, longtime Willkie client PAI Partners announced that it has entered into exclusive negotiations with Ergon Capital Partners (alongside the management team lead by CEO Christoph Gauer) for the acquisition of ELITech Group, the leading independent manufacturer of in-vitro medical diagnostics equipment, tests and reagents. The transaction is subject to customary works councils’ information and consultation procedure as well as antitrust clearance.
ELITech is a leading mid-sized fully integrated diagnostics platform developing equipment and reagents with strong positions in niche and growing sub-segments of molecular diagnostics, microbiology and clinical chemistry. With offices in Paris, London, Luxembourg, Madrid, Milan, Munich, New York and Stockholm, PAI Partners is a leading pan-European private equity firm that manages €8.3 billion of dedicated buyout funds.
The cross-border, multidisciplinary Willkie deal team is led by partner Eduardo Fernandez and includes: Paris -- national partners Gregory DeSaxcé, special European counsel Jeffrey Fouts and associates Marie Aubard and Camille Rezette (corporate); special European counsel Charles-Antoine Erignac and associate Perrine Saunier (regulatory); and partner David Tayar and associate Anouk Falgas (antitrust); New York -- partner Eugene Chang and associate Andrea de Vos (IP); counsel Jonathan Konoff (antitrust), associate Peter Melampy (corporate), law clerk Peter Coulson (litigation) and due diligence attorney Samuel Neill; and Milan -- Massimi Chiais, Elena Meloni, Anna Laura Pettoelle and Sarah Lo Piparo.